THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.

被引：0
|
作者：
Xin, Y. [1 ]
Collins, H. [1 ]
Cheng, F. [1 ]
Kwan, E. [1 ]
Ramanathan, S. [1 ]
Silverman, J. A. [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-049
引用
收藏
页码：S87 / S88
页数：2
相关论文
共 50 条
  • [1] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [2] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [4] Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment
    Xin, Yan
    Kawashima, Jun
    Weng, Winnie
    Kwan, Ellen
    Tarnowski, Thomas
    Silverman, Jeffrey A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 522 - 532
  • [5] Safety and pharmacokinetics of gadobenate dimeglumine (GD) in subjects with renal impairment.
    Lambrecht, LJ
    Davies, BE
    McCloud, S
    Parker, JR
    Swan, SK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 229 - 229
  • [6] Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
    Min, K. Chris
    Lasseter, Kenneth C.
    Marbury, Thomas C.
    Wrishko, Rebecca E.
    Hanley, William D.
    Wolford, Dennis G.
    de Haes, Joanna Udo
    Reitmann, Christina
    Gutstein, David E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 746 - 752
  • [7] PHARMACOKINETICS (PK) OF FENOFIBRIC ACID AND ROSUVASTATIN IN SUBJECTS WITH MILD TO MODERATE RENAL IMPAIRMENT.
    Zhu, T.
    Williams, L.
    Awni, W.
    Smith, W.
    Locke, C.
    Pradhan, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S27 - S27
  • [8] The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    CANCER RESEARCH, 2014, 74 (19)
  • [9] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    BLOOD, 2013, 122 (21)
  • [10] The pharmacokinetics and safety of darapladib in subjects with severe renal impairment
    Magee, Mindy He
    Shaddinger, Bonnie
    Collins, David
    Siddiqi, Shabana
    Soffer, Joseph
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (04) : 654 - 661
12345